Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Chris Heise - Senior Director, Biochemical & Cellular Pharmacology

Chris Heise

Senior Director, Biochemical & Cellular Pharmacology

"There is no place in the world that brings together such a strong emphasis on basic Biology with dedicated and experienced drug discoverers like Genentech."
Years at Genentech

I began my industrial career in 2003 working at Neurocrine Biosciences after completing a Ph.D. at the University of Virginia and a postdoctoral fellowship at Rockefeller University where I focused on the molecular characterization of G protein-coupled receptors. This first entry point into industry afforded me a great opportunity to integrate my academic training into the applied world of drug discovery and is where I began to hone my skills as a small molecule drug hunter. In 2007 I moved to Genentech to the department of Biochemical and Cellular Pharmacology where I’ve had the pleasure of working with some of the smartest scientists in the world attempting to discover novel small molecule modulators of diverse targets with the prospect of helping treat patients afflicted with life altering diseases. This work has spanned across multiple therapeutic areas with my most recent efforts focused on supporting and advancing the discovery of novel classes of antibiotics meant to treat infections caused by multi-drug resistant bacteria.

Featured Publication

Optimized arylomycins are a new class of Gram-negative antibiotics.

Nature. 2018 Sep;561(7722):189-194.

Smith PA, Koehler MFT, Girgis HS, Yan D, Chen Y, Chen Y, Crawford JJ, Durk MR, Higuchi RI, Kang J, Murray J, Paraselli P, Park S, Phung W, Quinn JG, Roberts TC, Rougé L, Schwarz JB, Skippington E, Wai J, Xu M, Yu Z, Zhang H, Tan MW, Heise CE